Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor

Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor

US Patent 10434092 · Granted Oct 8, 2019

Estimated economic value: $20,412,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Compounds and compositions for inhibiting the activity of HIF2-alpha and their m2025
Dosage regimen for a PI-3 kinase inhibitor2019
Pharmaceutical combinations2018
Combination of a PI3 kinase inhibitor with pacitaxel for use in the treatment or2018
Combination of a PI3 kinase inhibitor with pacitaxel for use in the treatment or2018
Pharmaceutical diagnostic2017
Synergistic combinations of PI3K- and MEK-inhibitors2017
Synergistic combinations of PI3K- and MEK-inhibitors2017
Short interfering ribonucleic acid (siRNA) for oral administration2016
Imidazoquinolines as dual lipid kinase and mTOR inhibitors2016
Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of 2016
S1P receptor modulators for treating relasping-remitting multiple sclerosis2015